Pharmacokinetic and Safety Study of Cenicriviroc and HMG-CoA Reductase Inhibitors, Caffeine and Digoxin
Status:
Completed
Trial end date:
2016-02-23
Target enrollment:
Participant gender:
Summary
This is a Phase 1, Open-Label, 3-Period, Single-sequence, Drug-drug Interaction Study in
Healthy Subjects to Assess the Effect of Cenicriviroc on the Pharmacokinetics (PK) of HMG-CoA
Reductase Inhibitors [Rosuvastatin (ROS), Atorvastatin (ATO) and Simvastatin (SIM)], Caffeine
and Digoxin